• Neomycin Sulfate: Precision in RNA/DNA & Ion Channel Researc

  2026-04-28

  Neomycin sulfate is more than a classic aminoglycoside antibiotic—it's a versatile tool for dissecting RNA/DNA structural interactions and modulating ryanodine receptor channels. Here, discover experimental workflows, troubleshooting insights, and practical benchmarks that set APExBIO’s Neomycin sulfate apart in advanced molecular assays.

• Zolmitriptan as a Research Tool: Beyond Migraine Models

  2026-04-28

  Explore Zolmitriptan’s role as a 5-HT1B receptor agonist in migraine research, with a focus on receptor selectivity, lysosomal crosstalk, and advanced assay design. Discover unique solubility and handling strategies for reliable, high-purity experimentation.

• Biomimetic Chromatography for Lung Drug Permeability Modelin

  2026-04-27

  This study systematically compares biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane chromatography (IAM-LC), both coupled with mass spectrometry, to model pulmonary drug absorption. The findings provide robust evidence that IAM-LC, in particular, offers predictive power for high-throughput screening of lung permeability, facilitating drug development and translational respiratory research.

• Quaternization Reprograms Lung Targeting in mRNA Nanoassembl

  2026-04-27

  This study demonstrates that N-quaternization of lipid-like nanoassemblies converts their organ tropism from spleen to lung, enabling highly selective mRNA delivery and protein expression in pulmonary tissue. The findings address a major challenge in non-liver mRNA therapies and offer a streamlined chemical strategy for organ-specific delivery.

• Fulvestrant (ICI 182,780): Optimizing ER Antagonism in Breas

  2026-04-26

  Fulvestrant (ICI 182,780) is a benchmark tool for dissecting estrogen receptor signaling, enabling robust workflows from apoptosis induction to resistance modeling in ER-positive breast cancer research. This guide delivers actionable protocols, advanced troubleshooting, and a translation of recent immunological findings for maximal experimental clarity.

• Advancing BBB Permeability Prediction with LLC-PK1-MDR1 Mode

  2026-04-25

  This study introduces a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction to significantly improve the predictive accuracy of CNS drug permeability. Rigorous validation with 41 compounds demonstrates the model’s robust correlation to in vivo brain distribution, offering a practical tool for early-stage CNS drug screening.

• Demethyleneberberine Induces NSCLC Senescence via c-Myc/HIF-

  2026-04-24

  This study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, suppresses non-small cell lung cancer (NSCLC) by inducing cell cycle arrest and senescence through downregulation of the c-Myc/HIF-1α pathway. The findings highlight DMB’s potential as a multi-pathway inhibitor in NSCLC research, with implications for overcoming resistance in cancer therapy.

• Sisomicin in Antibacterial Research: Protocols, Pitfalls, an

  2026-04-24

  Sisomicin, a broad-spectrum aminoglycoside antibiotic, remains a cornerstone in both Gram-negative and Gram-positive bacterial infection research. This guide delivers actionable workflows, troubleshooting insights, and comparative advantages, helping researchers leverage Sisomicin’s unique properties for robust, reproducible results in in vitro and in vivo models.

• Saquinavir for HIV Protease Inhibitor Workflows: Applied Adv

  2026-04-23

  Saquinavir empowers robust HIV protease inhibitor assays and next-generation permeability modeling, bridging antiretroviral drug research and translational applications. This article delivers actionable workflow enhancements, troubleshooting guidance, and practical insights from the latest biomimetic chromatography studies.

• Flumequine: Benchmark DNA Topoisomerase II Inhibitor for Ass

  2026-04-23

  Flumequine, a high-purity DNA topoisomerase II inhibitor, is validated for quantitative DNA replication research. With a defined IC50 and robust solubility profile, it enables reproducible enzyme inhibition studies and supports cancer pharmacology workflows.

• ω-Agatoxin IVA TFA: Precision Channel Blockade for Translati

  2026-04-22

  This article offers a strategic, mechanistic, and evidence-integrated roadmap for translational researchers leveraging ω-Agatoxin IVA TFA. It bridges fundamental neurophysiology with advanced experimental design, competitive landscape analysis, and actionable guidance for epilepsy and neuroprotection research, substantiated by rigorous citation and product intelligence.

• Q-VD-OPh: Bridging Apoptosis Mechanisms and Translational In

  2026-04-22

  Explore how Q-VD-OPh, a cutting-edge pan-caspase inhibitor, illuminates apoptotic pathways and advances neurodegenerative and cell viability research. This article delivers in-depth scientific context and practical guidance, distinct from existing resources.

• Applied Protocols for Angiotensin II in Vascular Remodeling

  2026-04-21

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is the benchmark tool for dissecting hypertension and vascular remodeling mechanisms, offering unmatched signal fidelity across cell and animal models. This article delivers precise workflows, troubleshooting strategies, and insight from recent vascular-neurodegeneration research for maximizing reproducibility with APExBIO’s Angiotensin II.

• Rab14 Activates Parkin-Dependent Mitophagy in Mitochondrial

  2026-04-21

  This study reveals that Rab14, a trans-Golgi network Rab-GTPase, enhances Parkin-mediated mitophagy, establishing a new regulatory role for Rab14 in mitochondrial quality control. The findings provide mechanistic insight into how Rab14-dependent pathways influence mitochondrial turnover, with implications for diseases involving mitophagy dysfunction.

• Bile Acid Metabolism Subtypes Reveal Prognostic Markers in C

  2026-04-20

  Feng et al. (2026) introduced an integrative transcriptomic subtyping of colorectal cancer based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers linked to immune dysfunction and prognosis. Their findings establish a mechanistic link between bile acid metabolic profiles and the tumor immune microenvironment, opening new avenues for risk stratification and therapeutic response assessment in CRC.

15575 records 1/1039 page Next 12345 下5页 Last page